

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company noted that “Although breast cancer is predominantly a disease of women, it does occur in men; the trial included, and the anticipated licence will include, both men and women. Therefore, Lilly intends to submit evidence to support appraisal across both sexes”.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No action needed as the company have stated they will not be excluding any population based on sex.

Committee will not make a recommendation based on sex.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Issue date: August 2021

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** H Edwards

**Date:** 20/08/2021